

30th December, 2023

The Dy. General Manager (Listing Dept.) BSE Limited., Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform that the Company has received communication(s) for collection of penalty from Indian tax authorities. The details as required under Regulation 30 of SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 are as below:

Name of the authority	Nature and details of the action taken, initiated or order passed	Date of receipt of direction or order, including any adinterim or interim orders, or any other communication from the authority	violation/ contravention committed or
Assistant	Order passed under	29 <sup>th</sup> December, 2023	The Order alleges
Commissioner of	Section 73 of the		wrongful claim of
Central Tax,	Goods and Service		transitional credit
Himayatnagar	Act, 2017, imposing a		(TRAN-2) of GST by
Division, Hyderabad	general penalty of		erstwhile Curatio
	₹ 25,000/-		Healthcare (I) Private
			Limited (Curatio) for
			tax period July-17 to
			Mar-18 and non-
			payment of interest.
			The Company had
			acquired Curatio in
			October 2022 which
			was subsequently
			merged into the
			Company.

TORRENT PHARMACEUTICALS LIMITED



Deputy Commissioner of State Tax, Guwahati, Assam		29th December, 2023	The Order alleges excess claim of input credit of GST for tax period July-17 to Mar-18
Assistant Commissioner of Central Tax, Ward 203 : Zone 11 : Delhi	Goods and Service	29 <sup>th</sup> December, 2023	The Order alleges excess claim of input credit of GST for tax period July-17 to Mar-18
Office of the Asst. Commr. Of Comml.Taxes, Koramangala, Bengaluru	1	28 <sup>th</sup> December, 2023	The Order alleges excess claim of input credit of GST for tax period July-17 to Mar-18

Impact on financial, operation, or other	Based on the Company assessment, an appeal
activities of the listed entity, quantifiable in	will be filed and the Company is hopeful of
monetary terms to the extent possible	favorable outcome at the appellate level and
	does not reasonably expect the said Order to
	have any material financial impact on the
	Company.
	2 0

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED